Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. 2006

Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
Division of Infectious Diseases, Case Western Reserve University, Center foe AIDS Research, University Hospitals of Cleveland, Cleveland, Ohio, USA.

OBJECTIVE To examine the effects of interferon-alpha (IFN-alpha) on T cell survival and activation in HIV infection. METHODS The effects of IFN-alpha on spontaneous apoptosis and CD38 expression among T cell subsets were determined in vitro and studied in relation to CD4 cell counts, plasma HIV RNA levels and the age of the subjects. METHODS Peripheral blood mononuclear cells from 48 HIV-infected persons and 17 healthy donors were incubated in vitro overnight with or without the addition of IFN-alpha. Percentages of apoptotic cells (positive for annexin V) and CD38 cells were determined among T cell subsets. RESULTS IFN-alpha inhibited spontaneous apoptosis of CD4 and CD8 T lymphocytes. This protective activity was impaired in CD4 T cells from HIV-infected persons. The reduced protection of IFN-alpha among CD4 cells from HIV-infected persons was not related to the percentages of activated (CD38 or CD45RO+CD38+) cells. Surprisingly, IFN-alpha induced CD38 expression among CD8 T cells from HIV-infected persons, and the magnitude of this effect was directly related to circulating CD4 T cell count. The CD8 T cell subset that expressed CD38 in response to IFN-alpha was defined as CD28 negative, CD62 ligand (CD62L) intermediate/negative. CONCLUSIONS Heightened expression of IFN-alpha in HIV infection may contribute to the phenotypic activation state that characterizes chronic infection while a diminished responsiveness of CD4 T cells to the protective effect of this cytokine may contribute to differential survival of CD4 and CD8 T cells in HIV disease.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
December 2011, Proceedings of the National Academy of Sciences of the United States of America,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
October 1995, European journal of immunology,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
December 1998, AIDS research and human retroviruses,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
October 2002, Current infectious disease reports,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
December 2008, Proceedings of the National Academy of Sciences of the United States of America,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
January 2022, Frontiers in public health,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
December 2014, Veterinary immunology and immunopathology,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
July 2000, The Journal of experimental medicine,
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
February 2017, Journal of acquired immune deficiency syndromes (1999),
Benigno Rodriguez, and Michael M Lederman, and Wei Jiang, and Douglas A Bazdar, and Kristen Gàrate, and Clifford V Harding, and Scott F Sieg
July 1994, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!